Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VaxInnate Inc.

www.vaxinnate.com

Latest From VaxInnate Inc.

VaxInnate snags $53m under BARDA contract extension

US biotech VaxInnate is gaining an additional $53m under its February 2011 contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop vaccines against influenza.

Infectious Diseases Neurology

Vivaldi inks NIAID CRADA for H7N9 vax, as infections top 200

Vivaldi Biosciences has inked a cooperative research and development agreement with the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to develop live attenuated influenza vaccine (LAIV) candidates against the novel H7N9 influenza virus, which has struck more than 200 people in China, killing more than 50.

Immune Disorders Infectious Diseases

CDC: Canadian H5N1 death poses 'very low' risk to North Americans

US health officials said the death of a Canadian from the H5N1 influenza virus, confirmed on 9 January by the World Health Organization (WHO), poses a "very low" risk to other people in the Americas.

Infectious Diseases Turkey

Seth Rudnick to chair G1 Therapeutics' board

G1 Therapeutics, a privately held pharmaceutical company focused on the discovery and development of novel small molecules for use in cancer therapy and biodefense, has named Dr Seth Rudnick executive chair of its board of directors – effective immediately. Prior to this position, Dr Rudnick was chair of the Chapel Hill, North Carolina-based firm's scientific advisory board – a role he will continue to play. Dr Rudnick is also a clinical professor of medicine at University of North Carolina and currently serves as chair of Liquidia Technologies, Drug Innovation Ventures at Emory (DRIVE) and Meryx, and on the boards of VaxInnate, POZEN and Square 1 Financial.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • VaxInnate Inc.
  • Senior Management
  • Wayne F Pisano, Pres. & CEO
    Kathleen McGowan, CFO
    Lynda Tussey, PhD, VP, R&D
    David Taylor, MD, CMO
    Christine Mayer, VP, Bus. Dev.
  • Contact Info
  • VaxInnate Inc.
    Phone: (609) 860-2260
    3 Cedar Brook Dr., Ste. 1
    Cranbury, NJ 08512
    USA
UsernamePublicRestriction

Register